Literature DB >> 14606515

Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats.

David G Little1, Rachel A Peat, Anthony Mcevoy, Paul R Williams, Elisabeth J Smith, Paul A Baldock.   

Abstract

UNLABELLED: Osteonecrosis (ON) of the femoral head in childhood can lead to loss of femoral head architecture and subsequent deformity. When femoral head ON was surgically induced in 24 rats, zoledronic acid treatment and prophylaxis improved sphericity and maintenance of architecture at 6 weeks. This preliminary experiment supports the use of bisphosphonates in childhood ON.
INTRODUCTION: We hypothesized that the bisphosphonate zoledronic acid could preserve femoral head structure while allowing bone repair.
MATERIALS AND METHODS: Osteonecrosis (ON) was surgically induced in the right femoral head of 24 female Wistar rats. The rats were randomized into three treatment groups and dosed subcutaneously with saline, zoledronic acid (0.1 mg/kg) at 1 and 4 weeks postoperation (ZA post), or zoledronic acid (0.1 mg/kg) given 2 weeks preoperation and at 1 and 4 weeks postoperation (ZA pre-post). After death at 6 weeks postoperation, undecalcified specimens were analyzed by DXA and standardized histomorphometric analysis.
RESULTS: Seventy-one percent of saline-operated femoral heads were aspherical (Mose score > 1), whereas only 13% and 0% of operated heads in the ZA-treated groups were aspherical (p < 0.05). DXA-measured bone mineral density in saline-treated femoral heads was reduced by 34% and 43% compared with the ZA-treated groups (p < 0.01). Histomorphometry showed decreases of 12% and 17% in bone volume (BV/TV) in saline groups compared with ZA post and ZA pre-post (p < 0.05), and a decrease in trabecular number (Tb.N) of 18% and 14% (p < 0.05), respectively. Bone formation rate (BFR) was increased by 56% in saline-treated operated heads over ZA post and was 4.8 times increased over the ZA pre-post group (p < 0.05). The differences in BV/TV and Tb.N in treated groups must therefore be caused by a reduction in bone turnover. Observational histology confirmed the retention of necrotic architecture in treated groups.
CONCLUSIONS: Zoledronic acid treatment and prophylaxis preserved femoral head architecture after traumatic ON in this rat model at 6 weeks. These data indicate that, by conserving femoral head architecture, bone repair may occur in conjunction with improved femoral head shape.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14606515     DOI: 10.1359/jbmr.2003.18.11.2016

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  32 in total

Review 1.  Evidence for using bisphosphonate to treat Legg-Calvé-Perthes disease.

Authors:  Megan L Young; David G Little; Harry K W Kim
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

Review 2.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Spontaneous osteonecrosis of the knee (SONK).

Authors:  S Breer; R Oheim; M Krause; R P Marshall; M Amling; F Barvencik
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-04-26       Impact factor: 4.342

4.  Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.

Authors:  S G Thakkar; C Isada; J Smith; M A Karam; J Reed; J W Tomford; K Englund; M Richmond; A Licata; C Hatch; M A Hussein
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

5.  Possible beneficial effect of bisphosphonates in osteonecrosis of the knee.

Authors:  Marius E Kraenzlin; Christian Graf; Christian Meier; Claude Kraenzlin; Niklaus F Friedrich
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2010-04-08       Impact factor: 4.342

6.  Local delivery of recombinant human bone morphogenetic proteins and bisphosphonate via sucrose acetate isobutyrate can prevent femoral head collapse in Legg-Calve-Perthes disease: a pilot study in pigs.

Authors:  Tegan L Cheng; Ciara M Murphy; Laurence C Cantrill; Kathy Mikulec; Clare Carpenter; Aaron Schindeler; David G Little
Journal:  Int Orthop       Date:  2014-01-04       Impact factor: 3.075

Review 7.  [Pain management in non-juvenile, aseptic osteonecrosis].

Authors:  M Jäger; A Werner; S Lentrodt; U Mödder; R Krauspe
Journal:  Schmerz       Date:  2004-12       Impact factor: 1.107

Review 8.  Use of bisphosphonates for the treatment of stress fractures in athletes.

Authors:  Yosuke Shima; Lars Engebretsen; Junji Iwasa; Katsuhiko Kitaoka; Katsuro Tomita
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-12-02       Impact factor: 4.342

Review 9.  The use of bisphosphonate in the treatment of avascular necrosis: a systematic review.

Authors:  Juliana Bahia Cardozo; Débora Motta S Andrade; Mittermayer B Santiago
Journal:  Clin Rheumatol       Date:  2008-02-13       Impact factor: 2.980

Review 10.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.